Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis scores second biosimilar approval in two weeks
BioPharma Dive
Thu, 06/29/17 - 09:43 am
Tags:
Novartis, biosimilars, Enbrel, Europe, Sandoz, Erelzi, Roche, Rituxan
[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
Motley Fool
Tue, 06/27/17 - 09:45 am
Tags:
AbbVie, biosimilars, Humira, Clovis Oncology, Rubraca, Novartis, Regeneron, Eylea
Little Alder bags positive PhIII migraine data, but giant rivals are racing ahead in a crowded field
Endpoints
Tue, 06/27/17 - 09:38 am
Tags:
Alder Biopharma, migraines, clinical trials, eptinezumab, Eli Lilly, Amgen, Novartis, Merck
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Tags:
Europe, EMA, hepatitis C, multiple sclerosis, breast cancer, renal cell carcinoma, AbbVie, Maviret, Gilead Sciences, Vosevi, Biogen, Amgen, Samsung Bioepis, biosimilars, Humira, Novartis, Kisqali, EUSA, Fotivda
Novartis picks up FDA approval for targeted lung cancer meds Tafinlar, Mekinist
Fierce Pharma
Fri, 06/23/17 - 03:35 pm
Tags:
Novartis, FDA, Tafinlar, Mekinist, non-small cell lung cancer, BRAF V600
What we know from BIO2017
BioPharma Dive
Fri, 06/23/17 - 11:30 am
Tags:
BIO2017, M&A, Novartis, Novo Nordisk, Seattle Genetics, ImmunoCellular Therapeutics
Novartis Drug Becomes First To Prevent Heart Attacks And Strokes By Targeting Inflammation
Forbes
Thu, 06/22/17 - 09:53 am
Tags:
Novartis, Ilaris, inflammation, heart attacks, strokes
Novartis trial results could spell trouble for Regeneron
Drug Delivery Business News
Wed, 06/21/17 - 07:33 pm
Tags:
Novartis, Regeneron, clinical trials, RTH258, neovascular age-related macular degeneration
5 Most Profitable Big Pharma Stocks on the Market Right Now
Motley Fool
Wed, 06/21/17 - 09:37 am
Tags:
Big Pharma, Gilead Sciences, Amgen, Novartis, Biogen, Bristol-Myers Squibb
Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch
Endpoints
Tue, 06/20/17 - 09:51 am
Tags:
Akcea, biotech, IPOs, Novartis
Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep
Endpoints
Tue, 06/20/17 - 09:20 am
Tags:
Novartis, Gamida Cell, clinical trials, cell grafts, bone marrow, leukemia, lymphoma
Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron
Endpoints
Tue, 06/20/17 - 08:51 am
Tags:
Novartis, Eylea, Regeneron, RTH258
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Endpoints
Mon, 06/19/17 - 03:16 pm
Tags:
Novartis, biosimilars, Rituxan, Roche, Sandoz
Novartis' Cosentyx racks up more long-term data in psoriatic arthritis and ankylosing spondylitis
Fierce Pharma
Thu, 06/15/17 - 05:36 pm
Tags:
Novartis, Cosentyx, psoriatic arthritis, ankylosing spondylitis
With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope
Endpoints
Wed, 06/14/17 - 09:45 pm
Tags:
Novartis, Google, Medicxi, biotech, Verily
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Endpoints
Mon, 06/12/17 - 09:24 pm
Tags:
Amgen, Novartis, Supreme Court, biosimilars, Neulasta, FDA, Coherus Biosciences
Novartis’s Next Challenge: Pricing Breakthrough Cancer Treatment
Bloomberg
Thu, 06/8/17 - 10:24 pm
Tags:
Novartis, drug pricing, CTL019, cancer, CAR-T
Novartis' CAR-T stacks up to Kite in lymphoma
BioPharma Dive
Wed, 06/7/17 - 07:04 pm
Tags:
Novartis, CAR-T, Kite Pharma, CTL019, axi-cel, lymphoma
July 12 FDA panel review looms as a watershed moment in Novartis’ campaign to win an historic new drug OK
Endpoints
Tue, 06/6/17 - 12:13 pm
Tags:
Novartis, FDA, CAR-T, advisory panels, CTL019, pediatric B-cell acute lymphoblastic leukemia
Novartis, IBM Watson collab to optimize care for patients with advanced breast cancer
Drug Delivery Business News
Mon, 06/5/17 - 12:07 pm
Tags:
Novartis, IBM Watson, advanced breast cancer, patients, breast cancer

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.